Indication

For the treatment of adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet

  • in combination with a statin or statin with other lipid‑lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid‑lowering therapies in patients who are statin‑intolerant, or for whom a statin is contraindicated

Medicine details

Medicine name:
inclisiran (Leqvio)
SMC ID:
SMC2358
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
Submission type
Full
Publication due date:
09 August 2021
SMC meeting date:
06 July 2021
Patient group submission deadline:
31 May 2021